[Market Focus] InBody Rises on Strong Q2 Results and Overseas Growth Expectations

InBody is showing strong performance. This is believed to be influenced by securities firms' analyses that, following robust second-quarter results, overseas sales are expected to increase.

As of 10:12 a.m. on August 14, InBody was trading at 29,100 won, up 1,100 won (3.93%) from the previous trading day.

In the second quarter, InBody recorded sales of 56.2 billion won and operating profit of 10.4 billion won, representing increases of 12% and 10%, respectively, compared to the same period last year. Kim Choonghyun, a researcher at Mirae Asset Securities, stated, "The company has set a new record for all-time high results for six consecutive quarters," adding, "Sales met market expectations, while operating profit exceeded them."

Mirae Asset Securities predicted that InBody will continue to see sales growth overseas. Researcher Kim Choonghyun explained, "Solid external growth is continuing, particularly in North America," and added, "Given that the company is expanding its sales bases and workforce across the United States, it is highly likely that growth centered on the U.S. market will continue for the next several years."

He further emphasized, "Since body composition analyzers are still a relatively unfamiliar concept overseas, InBody has aggressively expanded its sales force and strengthened its direct sales operations." He noted, "In the second quarter of this year, the number of employees increased by 25 from the previous quarter to 1,050, indicating that the aggressive hiring phase has likely concluded." He added, "We expect a gradual recovery in operating margin from the second half of this year onward."